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Structure and Bioactivity of Neuropeptide F from the Human Parasites
Schistosoma mansoni and Schistosoma japonicum
Abstract
The blood flukes Schistosoma mansoni and Schistosoma japonicuminflict immense suffering as agents of human
schistosomiasis. Previous investigations have found the nervous systems of these worms contain abundant
immunoreactivity to antisera targeting invertebrate neuropeptide Fs (NPFs) as well as structurally similar
neuropeptides of the mammalian neuropeptide Y (NPY) family. Here, cDNAs encoding NPF in these worms
were identified, and the mature neuropeptides from the two species differed by only a single amino acid. Both
neuropeptides feature the characteristics common among NPFs; they are 36 amino acids long with a
carboxyl-terminal Gly-Arg-X-Arg-Phe-amide and Tyr residues at positions 10 and 17 from the carboxyl
terminus. Synthetic S. mansoni NPF potently inhibits the forskolin-stimulated accumulation of cAMP in
worm homogenates, with significant effects at 10-11 M. This is the first demonstration of an endogenous
inhibition of cAMP by an NPF, and because this is the predominant pathway associated with vertebrate NPY
family peptides, it demonstrates a conservation of downstream signaling pathways used by NPFs and NPY
peptides.
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The blood flukes Schistosoma mansoni and Schisto-
soma japonicum inflict immense suffering as agents of
human schistosomiasis. Previous investigations have
found the nervous systems of these worms contain abun-
dant immunoreactivity to antisera targeting inverte-
brate neuropeptide Fs (NPFs) as well as structurally
similar neuropeptides of the mammalian neuropeptide
Y (NPY) family. Here, cDNAs encoding NPF in these
worms were identified, and the mature neuropeptides
from the two species differed by only a single amino
acid. Both neuropeptides feature the characteristics
common among NPFs; they are 36 amino acids long with
a carboxyl-terminal Gly-Arg-X-Arg-Phe-amide and Tyr
residues at positions 10 and 17 from the carboxyl termi-
nus. Synthetic S. mansoni NPF potently inhibits the for-
skolin-stimulated accumulation of cAMP in worm ho-
mogenates, with significant effects at 1011 M. This is the
first demonstration of an endogenous inhibition of
cAMP by an NPF, and because this is the predominant
pathway associated with vertebrate NPY family pep-
tides, it demonstrates a conservation of downstream sig-
naling pathways used by NPFs and NPY peptides.
Blood fluke parasites of the genus Schistosoma are the most
important metazoan parasites of humans and are the etiologi-
cal agents of schistosomiasis (bilharzia), which afflicts over 200
million people. Schistosomiasis ranks second, behind only ma-
laria, in terms of its overall negative socio-economic and public
health impact on the tropical and subtropical world, and it
remains among the top five disease priorities of the World
Health Organization (WHO)1 (1). Control of the disease rests
almost solely on chemotherapy using the anthelmintic prazi-
quantel (2–4). Most disturbingly, the long term utility of prazi-
quantel has been brought into question because of growing
reports of infections not responding to the recommended dos-
age (5–8) and worms with decreased sensitivity (9, 10). WHO
has accordingly identified research into the basic biology of
schistosomes as a priority, with the hope of identifying targets
for the next generation of antischistosomal drugs (1).
Schistosomes belong to the class Trematoda of the phylum
Platyhelminthes (flatworms) and, as such, are among the sim-
plest extant animals to display brain development with the
concomitant distinction between central and peripheral neuro-
nal elements. One distinct feature of platyhelminths and other
early diverging phyla is a prominent peptidergic component
within their nervous systems. One family of neuropeptides
abundant among these early animals is the neuropeptide F
(NPF) family (11–14). NPFs are 36–40-amino acid peptides
featuring a carboxyl-terminal Gly-Arg-X-Arg-Phe-amide
(GRXRF-NH2) motif and tyrosine residues at positions 10 and
17 relative to the carboxyl terminus.
These characteristics are common to those of vertebrate NPY
family peptides, 36 amino acid neuropeptides with RXR(F/Y)-
NH2 carboxyl termini, Tyr residues at positions 10 and 17
relative to the carboxyl termini, and prolines in a PXXPXXP
motif near the amino terminus (15, 16). These structural sim-
ilarities were the basis of the discovery of invertebrate NPFs,
as they were first localized using antisera targeting the car-
boxyl termini of NPY family neuropeptides (11). The striking
structural similarities between NPY family peptides and NPFs
notwithstanding, the evolutionary relationship between these
neuropeptides is not yet clear. One important aspect that re-
mains unresolved is the relationship between the signaling
pathways used by NPYs and NPFs. NPY family peptides act on
a structurally diverse family of G protein-coupled receptors
which, through Gi/o-mediated pathways, almost always pro-
duce an inhibition of cyclic AMP (cAMP) (15, 17, 18).
At present there is only indirect evidence for the occurrence
of NPY-like neuropeptides such as NPF in schistosomes. The
most compelling evidence is abundant and widespread immu-
noreactivity to antisera targeting pancreatic polypeptide, a
member of the NPY family of peptides (19–21). Here we iden-
tify cDNAs encoding NPFs from the blood fluke parasites
Schistosoma mansoni and Schistosoma japonicum. In addition,
the biological activity of S. mansoni NPF is measured and
discovered to activate potently the same signaling mechanism
stimulated by NPY family peptides in vertebrates.
EXPERIMENTAL PROCEDURES
Parasite Material—Schistosome-infected mice were supplied by The
Biomedical Research Institute (Rockville, MD) and housed at Iowa
State University. At 8 weeks post-infection, adult male and female
S. mansoni and S. japonicum were removed from the mesenteric vas-
culature, snap-frozen in liquid nitrogen, and stored at 80 °C.
Peptide Extraction and Chromatography—Approximately 10 g of
frozen adult S. mansoni were homogenized to a fine powder by using a
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R01-AI49162 (to T. A. D. and A. G. M.) and an Iowa Healthy Livestock
Initiative grant (to T. A. D. and M. J. K.). The costs of publication of this
article were defrayed in part by the payment of page charges. This
article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted
to the GenBankTM/EBI Data Bank with accession number(s) AY299474,
AY533028, AY662954.
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1 The abbreviations used are: WHO, World Health Organization;
DAP, distal adaptor primer; EST, expressed sequence tag; FaRP, FM-
RFamide-related peptide; HPLC, high performance liquid chromatog-
raphy; NPF, neuropeptide F; NPY, neuropeptide Y; PAP, proximal
adaptor primer; PTX, pertussis toxin; RACE, rapid amplification of
cDNA ends; mxNPF, M. expansa NPF; smNPF, S. mansoni NPF.
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pestle and mortar. Acid ethanol (EtOH, 0.7 M HCl; 3:1 v/w) was added
to allow the formation of a paste that was further diluted with acid
ethanol (total, 8:1 v/w) and stored overnight at 4 °C with continuous
mixing. The solution was centrifuged at 4000  g for 30 min to remove
microparticulates; ethanol was removed using a Rotavapor (R100,
Buchi), and a final concentration of 0.1% trifluoroacetic acid was added.
This was stored for 18 h at 4 °C, centrifuged for 1 h at 4000 g, and the
supernatant lyophilized.
The lyophilized extract was reconstituted in 4 ml of glacial acetic
acid, centrifuged for 30 min at 4000  g, and the supernatant loaded
onto a Sephadex G-50 (fine) column and eluted with 2 M glacial acetic
acid at a flow rate of 10 ml/h; fractions were collected every 15 min.
Fraction aliquots (10 l) were monitored by using a neuropeptide F
radioimmunoassay that employed an antiserum raised against the car-
boxyl-terminal decapeptide (YFAIIGRPRF-NH2) of Moniezia expansa
NPF (11). The assay sensitivity was 17 fmol of NPF per assay tube.
NPF-immunopositive fractions were subjected to reverse phase
HPLC using a Phenomenex C-18 column (24 0.49 cm) and eluted with
a linear gradient of 0.1% trifluoroacetic acid/CH3CN and 0.1% triflu-
oroacetic acid/H2O from 0:1 to 3:2 in 60 min at a flow rate of 1 ml/min.
Fractions (1 ml) were collected at minute intervals with absorbance
monitoring at 214 and 280 nm. Synthetic smNPF and GYIRFamide
were subjected to identical HPLC fractionation conditions.
Cloning of Schistosome Neuropeptide F-encoding cDNAs—Cloning
efforts focused on an S. japonicum expressed sequence tag (EST) po-
tentially encoding a partial neuropeptide F prepropeptide.2 Total RNA
was isolated from100 S. mansoni or S. japonicum adults by using TRI
Reagent (Sigma) and used to make separate amplified cDNA templates
for use in RACE reactions according to the protocol of Matz (22). Briefly,
first strand cDNA synthesis was driven by the dT variant primer TRsa.
After second strand synthesis, a pseudo-double-stranded adaptor con-
taining distal adaptor primer (DAP) sequence and proximal adaptor
primer (PAP) sequence was ligated to both the 5 and 3 ends of the
cDNA. The adaptor-ligated cDNA was then purified by using QIAquick
PCR purification kit (Qiagen) and amplified using the DAP and TRsa
primers for 20 cycles under the following conditions: 95 °C for 10 s,
65 °C for 30 s, and 72 °C for 2 min 30 s. All reagents, except primers,
were provided in the Marathon cDNA amplification kit (BD Bio-
sciences) and used according to the manufacturer’s instructions.
Seven gene-specific primers (F1–F7) for the S. japonicum EST were
designed for 3-rapid amplification of cDNA ends (RACE). Primers
F1–F6 were used in primary 3-RACE reactions with both the S. ja-
ponicum and S. mansoni cDNA, in conjunction with a DAP-TRsa 3
adaptor-specific primer. The Advantage 2 PCR kit (BD Biosciences) was
used for these reactions, and the components are as follows: 5 l of
DAP-TRsa (10 M), 1.0 l of gene-specific primer (10 M), 2.5 l of
cDNA, 5.0 l of 10 Advantage 2 Buffer, 1.0 l of dNTP mix (10 mM
each), 1.0 l of Advantage 2 Taq, and sterile distilled water to 50 l. The
cycle profile consisted of 30 cycles of 94 °C for 30 s, 65 °C for 2 min, and
72 °C for 1 min. Reactions were visualized on a 1% agarose gel contain-
ing 0.5 mg/ml ethidium bromide. Primary RACE products were subse-
quently diluted 1:50 with sterile distilled water and reamplified with
the appropriate nested gene-specific primer (F2–F7) in combination
with the nested 3 adaptor-specific primer TRsa. The components of
these reactions were as before except 1 l of each diluted primary RACE
reaction was used as template with 1 l of TRsa (10 M) and 1 l of
F2–F7 (10 M). The reamplification cycle conditions consisted of 30
cycles of 94 °C for 30 s, 65 °C for 1 min, and 72 °C for 1 min. Six
gene-specific 5-RACE primers (R1–R6) were also designed from the
S. japonicum EST. Primers R1–R5 were used in primary 5-RACE
reactions with both the S. japonicum and S. mansoni cDNA in conjunc-
tion with the DAP primer, otherwise the components of this reaction
were the same as for the primary 3-RACE reactions. The cycle profile
for the 5-RACE consisted of 30 cycles of 94 °C for 30 s, 65 °C for 1 min,
and 72 °C for 1 min. Additional 5-RACE reamplifications were carried
out as for the 3-RACE but using the appropriate nested gene-specific
primer (R2–R6) and the nested adaptor primer PAP. The reamplifica-
tion cycle profile was the same as for the primary 5-RACE.
Amplification of S. mansoni Genomic DNA—S. mansoni genomic
DNA was isolated from 50 worm pairs using the DNeasy tissue kit
(Qiagen). Based on the sequence information obtained through RACE
reactions, specific primers NPFgenF2 and NPFA2R were designed to
amplify a PCR fragment encompassing the open reading frame of the
S. mansoni NPF-encoding gene. Approximately 40 ng of genomic DNA
served as template in PCRs using the Advantage 2 PCR kit (BD Bio-
sciences). The components of these reactions are as follows: 1 l of each
primer (10 M), 40 ng of genomic DNA, 5.0 l of 10 Advantage 2
Buffer, 1.0 l of dNTP mix (10 mM each), 1.0 l of Advantage 2 Taq, and
sterile distilled water to 50 l. PCR cycle conditions were 30 cycles of
94 °C for 30 s, 59 °C for 1 min, and 72 °C for 1 min. Reactions were
visualized on a 1% agarose gel containing 0.5 mg/ml ethidium bromide.
Cloning and Sequencing—Discrete bands from RACE reactions and
genomic DNA amplifications were gel-purified using MinElute gel ex-
traction kit (Qiagen). The purified PCR products were cloned using
TOPO TA cloning kit for sequencing (Invitrogen), and colonies were
grown overnight in LB medium containing 100 mg/liter ampicillin.
Plasmid DNA was extracted from the cultures by using QIAprep spin
miniprep kit (Qiagen), and the presence of an insert of the expected size
was confirmed by digestion with EcoRI (New England Biolabs). Plas-
mids were sequenced using M13 forward and reverse primers, and raw
sequence data were edited by using Vector NTI software (Informax).
cAMP Assays—Adult S. mansoni (4–6 weeks post-infection) were
washed twice with cold cAMP buffer containing 50 mM sucrose, 50 mM
glycylglycine, 10 mM creatine phosphate, 2 mM MgCl2, 0.5 mM isobutyl-
methylxanthine, 1 mM dithiothreitol, 0.02 mM EGTA, 5 units of creatine
kinase, and 0.01% bovine serum albumin. The worms were kept on ice
for 5 min and then homogenized on ice for 2 min with a Teflon homog-
enizer. This preparation was centrifuged at 1000  g for 5 min, and the
pellet that included cell debris was discarded. The supernatant was
centrifuged at 40,000  g for 30 min at 4 °C. The supernatant was
discarded, and the pellet containing the cell membranes was resus-
pended in cAMP buffer with 0.1 mM ATP. This membrane preparation
was used for the cAMP assay, with each reaction containing mem-
branes from 3 worms.
The membrane mixture was incubated with various concentrations
of forskolin at 37 °C for 20 min to stimulate cAMP production. Forskolin
was dissolved in Me2SO with a final concentration of 0.1% Me2SO in
the reaction mixture, which had no measurable effect on cAMP. Con-
centrations of cAMP were determined using radioimmunoassay as de-
scribed previously (23). The lowest detectable quantity of cAMP in this
assay was 1.6 fmol per tube.
Peptides—The smNPF and the amino-terminally truncated analog
smNPF-(13–36) were generated at a 100-mol scale using a 433A
peptide synthesizer (Applied Biosystems, UK) and Rink amide 4-meth-
ylbenzhydrylamine resin (24). Peptide elongation was effected using
2-(1H-benzotriazole-1-y)-1,1,3,3-tetramethyluronium hexafluorophos-
phate/N-hydroxybenzotriazoleH2O/N,N-diisopropylethylamine (1:1:2
v/v/v) and a 10-fold molar excess of each N-Fmoc (N-(9-fluorenyl)me-
thoxycarbonyl)-protected amino acid. Peptides were cleaved from the
resin by a 2-h incubation at room temperature in trifluoroacetic acid/
thioanisole/triisopropylsilane/water (96:2:1:1 v/v) and then separated
from the resin by filtration under pressure, precipitated with diethyl
ether several times, and lyophilized. Peptide purity was analyzed by
reverse phase HPLC by using a Phenomenex C5 column (25  0.46 cm)
and eluted with a linear gradient of 0.05% trifluoroacetic acid/CH3CN
and 0.05% trifluoroacetic acid/H2O from 1:49 to 3:2, flow rate 1 ml/min
with detection at  214 nm. Peptide identity was verified by electro-
spray mass spectroscopy using a Finnigan LCQ Ion Trap Mass
Spectrometer.
Porcine NPY (pNPY), pNPY-free acid (pNPYFA), human PP (hPP),
and porcine PYY (pPYY) were obtained from American Peptide Co.
Moniezia expansa NPF (mxNPF) was synthesized by CloneStar-UK.
The platyhelminth FMRFamide-related peptides (FaRPs) GYIRF-
amide, RYIRFamide, and YIRFamide were synthesized by Research
Genetics/Invitrogen.
Bioinformatics—BLAST searches were performed at National Cen-
ter for Biotechnology Information (NCBI). SignalP analysis was exe-
cuted on The World Wide Web Prediction Server at the Center for
Biological Sequence Analysis, with truncation set at the default of 70
amino-terminal amino acid residues. Alignments were produced with
the ClustalW algorithm by Vector NTI software (Informax).
RESULTS
The earliest indication of an NPF-like neuropeptide in schis-
tosomes was the widespread immunoreactivity with antisera
targeting NPY family peptides observed throughout the nerv-
ous system of schistosomes (19–21). Substantiating this, in
S. mansoni acid ethanol extracts there is a fraction immuno-
reactive with M. expansa NPF (mxNPF) antiserum (Fig. 1). The
mxNPF radioimmunoassay detected only a single peak in
2 GenBankTM accession number BU776442 submitted by the Chinese
National Human Genome Center, Shanghai, China.
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S. mansoni following gel permeation and HPLC fractionation.
The mxNPF-immunoreactive molecule co-eluted with synthetic
mxNPF, indicating that the schistosome peptide was of similar
size to mxNPF. Unfortunately, even in the extracts from over
10,000 schistosomes, the low levels of recovery of NPF-immu-
noreactivity coupled with the complex nature of whole S. man-
soni extracts negated peptide isolation, sequencing, and mass
analysis. Therefore, we turned to molecular approaches to iden-
tify the structure of the NPF-immunoreactive molecule.
Identification of NPF-encoding cDNAs—In order to identify
schistosome NPF, we focused on the GRPRFGKR motif. This
includes the highly conserved GRPRF carboxyl-terminal pen-
tapeptide of known mature NPFs (see Fig. 3), the adjacent Gly
which serves as a donor for the amidation reaction, and the
common Lys-Arg dibasic cleavage site. Extensive attempts to
identify S. mansoni NPF by using degenerate primers target-
ing this Arg-rich motif were without success. A BLAST search
using the GRPRFGKR motif against the translated schisto-
some ESTs at the National Center for Biotechnology Informa-
tion found that the S. japonicum EST SJECNA01 potentially
encodes this sequence. In addition, the hypothetical protein
contains a Tyr residue at position 10 relative to the carboxyl-
terminal Phe, another feature common to all known NPFs.
Sequence-specific primers targeting this EST were generated
and used in RACE PCR with cDNA templates from both
S. japonicum and S. mansoni.
To characterize the full-length transcript of the S. japonicum
EST, we designed seven forward and six reverse gene-specific
primers from the EST sequence. These primers were used in 3-
and 5-RACE PCR with an amplified cDNA template generated
from adult S. japonicum tissue. A 779-nucleotide transcript
was identified that includes a 438-nucleotide open reading
frame encoding a putative 146-amino acid protein.3 The tran-
script also featured a polyadenylation signal (AATAAA) 22
nucleotides upstream of a poly(A) tail.
To determine whether a homologous gene was expressed in
S. mansoni, the S. japonicum-specific RACE primers were also
used in 3- and 5-RACE PCR with an S. mansoni cDNA tem-
plate, constructed in an identical manner to the S. japonicum
cDNA. The S. japonicum primers successfully amplified from
the S. mansoni cDNA template a 787-nucleotide transcript
with a 441-nucleotide open reading frame encoding a putative
147-amino acid protein.4 The transcript includes two conserved
polyadenylation signals (AATAAA) 16 and 22 nucleotides, re-
spectively, upstream of a poly(A) tail.
The S. japonicum and S. mansoni NPF cDNAs each have a
single open reading frame, but because each has multiple po-
tential initiation codons, the length of the prepropeptide is not
clear. For example, the S. mansoni cDNA could encode four
different proteins ranging 147 to 127 amino acids, and the
S. japonicum prepropeptide could range from 146 to 126 resi-
dues (Fig. 2). All known prepro-NPFs feature a signal peptide
in the amino-terminal region adjacent to the mature peptide.
SignalP analysis finds a signal peptide in each of the possible
schistosome prepro-NPFs, with the exception of the potential
147-amino acid S. mansoni prepro-NPF. In mxNPF, the only
other NPF identified thus far in a parasitic platyhelminth, the
amino terminus of the 40-amino acid mature peptide is gener-
ated by cleavage at a single basic residue (11, 25). Both schis-
tosome prepro-NPFs have a single basic residue at a site that
would generate a 36-amino acid mature peptide (Fig. 2). The
prepro-NPFs from both species also include conserved dibasic
residues for carboxyl-terminal cleavage, resulting in propep-
tides with a carboxyl-terminal Gly residue required for the
production of the -amide group conserved among all known
NPFs and NPY family neuropeptides. By assuming the earliest
possible start site, the prepropeptides are 62% identical; the 36
amino acid mature neuropeptides are 97% identical between
the 2 species, differing only by a single amino acid (Fig. 2 and
Table I).
Both putative mature peptides have features that define
NPFs (Fig. 3). The carboxyl-terminal GRPRF-NH2 motif is
conserved, which is not surprising because this was the basis of
the identification of these peptides. The peptides also have Tyr
residues at positions 10 and 17 relative to the carboxyl termi-
nus, residues that are conserved in all NPFs and virtually all
NPY family peptides (13, 16). The flatworm NPFs also include
residues hypothesized to be present in the ancestral NPY fam-
ily peptide (16): Lys19, Leu24, and Leu30 (Fig. 3). NPY family
peptides feature a highly conserved PXXPXXP motif in the
amino-terminal half of the mature neuropeptides, but NPFs
generally lack this feature. The amino-terminal half of schis-
tosome NPFs is devoid of Pro residues but does possess a Phe11
conserved among all but one of the flatworm and molluscan
NPFs (Fig. 3).
To confirm that the 36-amino acid peptide predicted by the
S. mansoni cDNA was the molecule originally identified by
mxNPF immunoreactivity, the elution position of synthetic
smNPF was compared with that of the mxNPF immunoreac-
tivity in S. mansoni acid ethanol extracts. The immunoreactive
fraction from S. mansoni co-eluted with synthetic smNPF (Fig.
1), supporting their structural similarity.
S. mansoni Gene Organization—The initial identification of
NPF in a platyhelminth was from M. expansa. The gene encod-
ing mxNPF features a phase 2 intron that is conserved among
many NPY-encoding genes and that represents a possible link
between invertebrate NPFs and vertebrate NPYs. To examine
for the presence of introns, the S. mansoni gene was amplified
from a genomic DNA template isolated from adult S. mansoni
worms. The primers used in this PCR, NPFgenF2 and
NPFA2R, were based on sequence obtained through 3- and
3 The S. japonicum NPF cDNA has GenBankTM accession number
AY533028. 4 The smNPF cDNA has GenBankTM accession number AY299474.
FIG. 1. Chromatograph of mxNPF immunoreactivity in etha-
nol extracts of S. mansoni compared with the elution profile of
synthetic flatworm neuropeptides. The dashed line viewed against
the right y axis indicates the results of radioimmunoassay by using an
mxNPF antiserum (11) against an acid ethanol extract of mixed-sex,
adult S. mansoni. The radioimmunoassay was performed against the
fractions collected at 1-min intervals following fractionation on a Phe-
nomenex C-18 analytical column eluted with a linear gradient of 0.1%
trifluoroacetic acid/CH3CN (0–60% in 60 min). The major peak of
mxNPF immunoreactivity in the schistosome sample is in the fraction
collected in the 41st min. The solid lines show the 214- and 280-nm
absorbance profiles for synthetic GYIRFamide and smNPF under the
same conditions. Synthetic smNPF, the 36-amino acid amidated neu-
ropeptide predicted by the smNPF cDNA, co-elutes with the major peak
of mxNPF immunoreactivity recovered from the worm extracts.
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5-RACE and were designed to amplify a 792-nucleotide region
of cDNA including the entire putative open reading frame of
the gene.5 The resulting genomic amplicon was also 792 nucle-
otides in length and was confirmed upon sequencing to contain
no introns.
Cyclic AMP Inhibition—The closest structural analogs of
invertebrate NPFs are members of the NPY family of peptides
that act upon a family of receptors collectively designated Y
receptors (17, 18). All known Y receptors are G protein-coupled,
and all can be linked to inhibition of adenylyl cyclase through
pertussis toxin-sensitive G proteins, either Gi or Go. All of
the Y receptor subgroups have been shown to inhibit the accu-
mulation of forskolin-stimulated cAMP, such that the inhibi-
tion of adenylyl cyclase has been referred to as the universal
signaling mechanism of Y receptors (26). Therefore, we hypoth-
esized that smNPF could act on its cognate receptor to inhibit
the accumulation of forskolin-stimulated cAMP in schistosome
homogenates.
We found that forskolin-stimulated cAMP accumulation in
the homogenates was very similar to previous reports (27).
With 100 M forskolin for 20 min, cAMP accumulation was
almost 400% of basal, and at 10 M it was 258  23% (Fig. 4A).
We used 10 M forskolin for subsequent assays. Synthetic
smNPF produced a potent inhibition, with a threshold at 10 pM
and an IC50 of 170 pM (Fig. 4B). A maximum effect was pro-
duced near 10 nM with 70% inhibition. The carboxyl-terminal
24 amino acids of smNPF (smNPF-(13–36)) was only slightly
less potent, with an IC50 of 370 pM, and as with the holopeptide,
smNPF-(13–36) had a maximal effect of 70% inhibition. The
smNPF-mediated inhibition of cAMP was blocked by preincu-
bation with 100 ng/ml PTX, indicating that the effect of the
neuropeptide is transduced by Gi or Go (Fig. 5A). smNPF
also inhibited cAMP accumulation in the absence of forskolin
stimulation. However, because the level of cAMP in the un-
stimulated homogenates was variable and relatively low, the
results were much more erratic. For example, 1 M smNPF
inhibited cAMP accumulation by over 60% in one experiment,
but the average was 41  19% in three experiments.
M. expansa NPF (mxNPF) also produced a concentration-de-
pendent inhibition of cAMP accumulation, but it was orders of
magnitude less potent (Fig. 4B). The threshold was 10 nM, the
same concentration at which smNPF produced a maximal ef-
fect. mxNPF is overall only 25% identical and 44% similar to
smNPF, but the similarity is concentrated in the carboxyl-
terminal region, where the last five residues are identical
(GRPRF-NH2) and seven of the last nine are similar. However,
the nine carboxyl-terminal residues of mxNPF could not mimic
the smNPF effect on cAMP, producing no inhibition at concen-
trations as high as 10 M.
The structurally similar vertebrate peptides porcine NPY
(pNPY) and human pancreatic polypeptide (hPP) produced a
concentration-dependent inhibition of cAMP accumulation in
the schistosome homogenates, but were dramatically less po-
tent than smNPF. The only NPY family peptide tested that did
not produce significant inhibition at 10 M was porcine peptide
YY (pPYY). It is difficult to attribute the efficacy of these
neuropeptides to any particular carboxyl-terminal motif, be-
cause the rank order of potency for smNPF and its analogs was
smNPF ( . . . GRPRF-NH2)  mxNPF ( . . . GRPRF-NH2) 
pNPY ( . . . TRQRY-NH2)  hPP ( . . . TRPRY-NH2)  pPYY
( . . . TRQRY-NH2), except that a GRPRF-NH2 motif was more
effective than the TRXRY-NH2 motif (Table II). Although NPY
was effective, NPY without a carboxyl-terminal amide was
without effect, demonstrating a requirement for this carboxyl-
terminal modification (Fig. 5B).
In addition to NPFs, another class of amidated peptides,
designated FaRPs, have been found in worms of this phylum
(13, 20, 28). Like NPFs, FaRPs possess a carboxyl-terminal
RF-NH2 signature. All of the platyhelminth FaRPs identified
thus far (RYIRF-NH2, GYIRF-NH2, and YIRF-NH2) were with-
out effect on cAMP at concentrations as high as 10 M (Fig. 5C).
DISCUSSION
The cDNAs identified here in two species of schistosomes
encode peptides that share the defining characteristics of
NPFs. Furthermore, the neuropeptide sequence encoded by the
S. mansoni cDNA has potent (threshold of 0.01 nM and IC50 of
0.170 nM) inhibitory effects on cAMP accumulation in homoge-
nates from these worms.
The cDNAs cannot, however, provide unequivocal identifica-
tion of the mature neuropeptides; in the absence of sufficient
tissue for biochemical purification, that certainty is lacking.
5 The smNPF genomic sequence has GenBankTM accession number
AY662954.
TABLE I
Comparison of prepropeptides of S. japonicum NPF and smNPF
Longest
possible
prepropeptide
Amino-terminal
extension Propeptide
Carboxyl-
terminal
extension
S. mansoni 147 aaa 63 aa 37 aa 47 aa
S. japonicum 146 aa 61 aa 37 aa 48 aa
% similar 71% 67% 100% 54%
% identical 62% 55% 97% 46%
a aa, amino acids.
FIG. 2. Predicted NPF prepropeptides from S. mansoni and S. japonicum. Amino-terminal peptide flanking the mature neuropeptide is
on the top line, the propeptide is in the middle, and the carboxyl-terminal flanking peptide is on the bottom line. The figure includes the amino acids
that would be encoded by the longest possible open reading frame, but both contain more than one potential initiation codon. Those denoted with
() above the sequence result in peptides containing a signal peptide as identified by SignalP; a peptide initiated at the first Met in the S. mansoni
open reading frame (E) is predicted to lack a signal peptide. Regardless of which Met represents the beginning of the prepropeptide, SignalP
identifies the same single cleavage site in each peptide, and the first residue of the cleaved peptide is denoted with (). The site of the second
amino-terminal cleavage is identified at a conserved single basic residue (f). Also present are dibasic cleavage sites producing the carboxyl-
terminal of the propeptides (). The span that includes the predicted mature peptides, in the middle rows, includes only a single amino acid
difference. Identical residues are blocked in black, and similar residues are blocked in gray.
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However, a number of considerations suggest that the 36-
amino acid mature peptide utilized for the biochemical studies
here is the endogenous neuropeptide. First, size fractionation
and HPLC did not distinguish between the endogenous mxNPF
immunoreactive molecule in S. mansoni extracts and the syn-
thetic 36-amino acid amidated smNPF. Second, if the schisto-
some prepro-NPFs are processed like the only other known
parasitic flatworm NPF, the 36-amino acid mature peptide
would result. For M. expansa, because both the cDNA and
mature peptide have been identified (11, 25), it is known that
cleavage at a single basic residue produces the amino terminus
of the mature peptide. Both schistosome prepro-NPFs have a
single basic residue where cleavage would produce the 36-
amino acid mature peptide. Finally, the potency of smNPF36
on cAMP inhibition in schistosome homogenates strongly sup-
ports its designation as an endogenous signaling molecule in
the worms.
The potency of smNPF inhibition of cAMP also leaves little
doubt that this is an associated endogenous biochemical path-
way in the worms. NPY family peptides exert their effects
through the activation of a family of G protein-coupled recep-
tors termed Y receptors. All five Y receptor subtypes produce
an inhibition of adenylate cyclase, whereas two subtypes also
produce elevation of cytoplasmic Ca2 (29–32). The inhibition
of cAMP is so closely associated with Y receptors that it has
been referred to as the universal signaling mechanism among
them (18, 26). The inhibition of cAMP in schistosome homoge-
nates by smNPF demonstrates a conservation of signaling be-
tween this NPF and NPY family peptides. The conservation of
this signaling pathway has been suggested in the mollusc Lym-
FIG. 3. Alignment of schistosome NPFs with those of other platyhelminths, molluscs, and a putative NPY family peptide progen-
itor. The lower grouping shows the flatworm and mollusc NPFs. The GRPRF-NH2 motif is conserved, as are Tyr residues at positions 10 and 17
relative to the carboxyl terminus of the mature peptide. The alignment demonstrates that the conservation of the structure is much less in the
amino-terminal half of the neuropeptides and greater in the carboxyl-terminal half, culminating in the identical carboxyl-terminal pentapeptide
amide. Identical residues are blocked in black, and similar residues are blocked in gray. Above the invertebrate neuropeptides is a postulated NPY
family peptide progenitor (16). The residues conserved between this peptide and the schistosome NPFs are underlined, and they include three
residues not seen in all NPFs: Lys19, Leu24, and Leu30.
FIG. 4. Concentration-dependent effects of forskolin and neuropeptides on cAMP levels. A, forskolin stimulation of cAMP accumula-
tion in S. mansoni homogenates. B, concentration dependence of its inhibition by synthetic smNPF and similar neuropeptides. The forskolin
stimulation of cAMP in schistosomes has been reported previously (27, 37), and the results obtained here are very similar. If the forskolin
incubations included smNPF, the accumulation of cAMP in the homogenates was inhibited in a concentration-dependent fashion, with a maximum
inhibition of almost 70% of the stimulated cAMP. Synthetic schistosome peptides were the most potent by a wide margin, but other structurally
similar peptides also produced a concentration-dependent inhibition of cAMP. For each data point, at least four different samples were tested on
at least 2 different days, and the points displayed are the mean  S.E.
FIG. 5. Inhibition of forskolin-stimulated cAMP production by neuropeptides. A, the smNPF-mediated inhibition is blocked by
preincubation of the homogenate with PTX (100 ng/ml), indicating a role for Gi/o in the transduction of the smNPF. PTX alone did not have a
significant effect. B, both smNPF and the carboxyl-terminal fragment smNPF-(13–36) inhibited cAMP accumulation. However, although mxNPF
was effective, the carboxyl-terminal fragment mxNPF-(31–39) was without significant effect. Absence of the carboxyl-terminal amide, as seen in
pNPY free acid (pNPYFA), abolished the inhibitory effects demonstrating that the effect measured here is mediated by a receptor selective for
amidated neuropeptides. C, the effect of smNPF on cAMP is not mimicked by any of the platyhelminth FMRFamide-related peptides. All the data
are from at least four different samples tested on at least 2 different days, and displayed are the mean  S.E.
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naea stagnalis (33) and Drosophila (34), where receptors re-
sponding to NPFs couple to cAMP inhibition in heterologous
expression systems. However, this is the first demonstration of
an endogenous inhibition of cAMP by an invertebrate NPF.
These results therefore provide a more substantial link be-
tween NPF receptor-mediated signaling pathways in inverte-
brates and those of vertebrate NPY family peptides. These
results also indicate that NPY/NPF signaling systems were
present within more basal metazoa as platyhelminths are
thought to have diverged prior to molluscs or arthropods (35).
The inhibition results with various NPFs and NPY family
peptides show that the GRPRF-NH2 carboxyl-terminal motif
found in NPFs is more potent than is the TRQRY-NH2 or
TRPRY-NH2 motif of many NPY family peptides. However, the
ultimate efficacy of the neuropeptide is not determined solely
by the carboxyl-terminal motif, because there is a dramatic
difference in potency between smNPF and mxNPF, which both
end in GRPRF-NH2.
In total, the data reported here strengthen the hypothesis
that invertebrate NPFs are related to NPY family peptides.
First, the structures of S. japonicum NPF and smNPF add to
the growing number of invertebrate neuropeptides with con-
spicuous similarities with NPY family peptides and the puta-
tive NPY family progenitor (16): 36 amino acid peptides with
conserved Tyr residues at positions 10 and 17 relative to an
RXR(F/Y)-NH2 carboxyl terminus. Second, the schistosome
peptides feature three additional residues (Lys19, Leu24, and
Leu30) that are common to the hypothesized NPY family pro-
genitor, thereby providing an additional although weak link
between flatworm NPFs and NPYs. Finally, as discussed
above, the demonstration of continuity in the biochemical sig-
naling pathway activated by smNPF and NPY family peptides
supports the relationship between these neuropeptides.
The evidence is that NPF is the most abundant neuropeptide
in these medically important parasites (19–21, 36) and that the
peptide has extremely potent biochemical effects in the worm,
which provides appeal to the NPF signaling system as a poten-
tial target for antischistosomal drugs. However, the conserva-
tion of structure with mammalian NPY family neuropeptides
and the conservation of downstream biochemical signaling
demonstrated here indicate similarities between the receptors
for NPFs and vertebrate NPYs that could present a challenge
in developing selective receptor pharmacophores. Regardless,
the data presented here are a significant step toward under-
standing the biology of the most abundant neuropeptide in
these parasites that continue to inflict an immense amount of
suffering throughout the world.
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TABLE II
Neuropeptides tested for their ability to inhibit the accumulation of forskolin-stimulated cAMP in S. mansoni homogenates
Peptide Denotation in text Amino acid sequence IC50 in cAMP assay
S. mansoni NPF smNPF AQALAKLMSLFYTSDAFNKYMENLDAYYMLRGRPRF-NH2 170 pM
S. mansoni NPF12–36 smNPF13–36 TSDAFNKYMENLDAYYMLRGRPRF-NH2 370 pM
M. expansa NPF mxNPF PDQDAIVNPSDLVLDNKAALRDYLRQINEYFAIIGRPRF-NH2 	1 M
M. expansa NPF31–39 mxNPF31–39 FAIIGRPRF-NH2 NA
a
Porcine neuropeptide Y pNPY YPSKPDNPGEDAPAEDLARYYSALRHYINLITRQRY-NH2 	1 M
Porcine neuropeptide Y free acid pNPYFA YPSKPDNPGEDAPAEDLARYYSALRHYINLITRQRY- NA
Porcine neuropeptide Y1–24 pNPY1–24 YPSKPDNPGEDAPAEDLARYYSAL NA
Human pancreatic polypeptide hPP APLEPVYPGDNATPEQMAQYAADLRRYINMLTRPRY-NH2 1 M
Porcine peptide YY pPYY YPAKPEAPGENASPEELSRYYASLRHYLNLVTRQRY-NH2 NA
Flatworm FaRP YIRF-NH2 NA
Flatworm FaRP GYIRF-NH2 NA
Flatworm FaRP RYIRF-NH2 NA
a NA, no activity.
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